⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALNY News
Alnylam Pharmaceuticals, Inc.
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
prnewswire.com
VRTX
ALNY
BEAM
SANA
Form 8-K
sec.gov
ALNY
Alnylam Issues 2025 Corporate Responsibility Report
businesswire.com
ALNY
Next Generation Drug Conjugates Market 2026-2035 - Expansion into Non-Oncology Therapeutic Areas Present Opportunities for the $15.75 Billion Market
globenewswire.com
AZN
PFE
NVS
ALNY
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
globenewswire.com
IONS
ALNY
NVS
BIIB
ARWR
SLN
WVE
VNDA
NSP
TCRT
AMX
CDIO
SRPT
VIR
BNTX
ARCT
GSK
PFE
De nouvelles analyses de données présentées lors du congrès Heart Failure 2026 démontrent les bénéfices cliniques solides et constants du vutrisiran en tant qu’option thérapeutique de première intention chez toutes les populations
businesswire.com
ALNY
Heart Failure 2026: Neue Datenanalysen belegen robusten und konsistenten klinischen Nutzen von Vutrisiran als Erstlinien-Behandlungsoption für ATTR-CM-Patientenpopulationen – auch bei hoher Krankheitslast
businesswire.com
ALNY
The Inner Circle acknowledges Ilene Fennoy, MD, MPH as a Pinnacle Professional Member Inner Circle of Excellence
prnewswire.com
COLB
SNY
BMY
PFE
MRK
JNJ
ABBV
GILD
AMGN
REGN
BIIB
CRSP
VRTX
MDLZ
KHC
PEP
KO
SBUX
MCD
YUM
CMG
TSLA
NVDA
GOOG
MSFT
AMZN
META
IBM
ORCL
CSCO
ADBE
CRM
INTC
AMD
QCOM
MU
SMCI
ACN
NOW
PANW
SNPS
CDNS
MRVL
LRCX
KLAC
ASML
AMAT
NXPI
ON
INFY
WMT
COST
HD
LOW
TGT
BBY
MGM
LVS
WYNN
MAR
HPE
HPQ
DELL
XRX
GE
BA
LMT
RTX
GD
NOC
CAT
DE
HON
MMM
AXP
V
MA
JPM
BAC
WFC
GS
MS
DIS
CMCSA
NFLX
T
VZ
CHTR
TMUS
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
IQ
BILI
EDU
RLX
LI
XPEV
NIO
CPT
M
KSS
ROST
TJX
URBN
PVH
RL
AEO
ANF
LULU
UA
NKE
CROX
EAT
SJM
GIS
ADM
IFF
CPB
KDP
MNST
STZ
CCEP
BUD
MOLN
CRBU
EDIT
NTLA
BEAM
ALNY
AZN
BNTX
MRNA
XBIT
RBLX
EXAS
CRWD
FTNT
OKTA
DDOG
SNOW
PLTR
AI
UPST
PYPL
COIN
MARA
CLSK
RIOT
BTBT
MSTR
Resumen: Los nuevos análisis de datos presentados en Heart Failure 2026 demuestran un beneficio clínico importante y consistente de vutrisiran como opción terapéutica de primera línea en todas las poblaciones de pacientes con ATTR-CM, incluyendo aquellos...
businesswire.com
ALNY
Riassunto: Le nuove analisi dei dati presentate al congresso Heart Failure 2026 dimostrano un beneficio clinico notevole e costante di vutrisiran come opzione terapeutica di prima linea in tutte le popolazioni di pazienti affetti da ATTR-CM, compresi quelli...
businesswire.com
ALNY